The role of Janus kinases in haemopoiesis and haematological malignancy (Q36527760)

14 August 2017

1 reference

title

The role of Janus kinases in haemopoiesis and haematological malignancy (English)

1 reference

14 August 2017

1 reference

Asim Khwaja

1

1 reference

14 August 2017

language of work or name

English

0 references

publication date

5 July 2006

1 reference

British Journal of Haematology

14 August 2017

published in

1 reference

14 August 2017

volume

134

1 reference

14 August 2017

issue

4

1 reference

14 August 2017

page(s)

366-384

1 reference

The YXXQ motif in gp 130 is crucial for STAT3 phosphorylation at Ser727 through an H7-sensitive kinase pathway

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Clinical implications of the JAK2 V617F mutation in essential thrombocythemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Janus kinase (Jak) subcellular localization revisited: the exclusive membrane localization of endogenous Janus kinase 1 by cytokine receptor interaction uncovers the Jak.receptor complex to be equivalent to a receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

JAK2 V617F mutation, PRV-1 overexpression and endogenous erythroid colony formation show different coexpression patterns among Ph-negative chronic myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Gain of chromosome arm 9p is characteristic of primary mediastinal B-cell lymphoma (MBL): comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Cytoplasmic protein tyrosine phosphatases, regulation and function: the roles of PTP1B and TC-PTP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Hypermethylation of the suppressor of cytokine signalling-1 (SOCS-1) in myelodysplastic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

The role of STATs in transcriptional control and their impact on cellular function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Reduced lymphomyeloid repopulating activity from adult bone marrow and fetal liver of mice lacking expression of STAT5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Gene therapy for severe combined immunodeficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

SOCS1 and SHP1 hypermethylation in mantle cell lymphoma and follicular lymphoma: implications for epigenetic activation of the Jak/STAT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Chronic myeloproliferative disorders: a tyrosine kinase tale.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Serine phosphorylation of STATs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

SOCS: role in inflammation, allergy and homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Tyrosine phosphorylation of Jak2 in the JH2 domain inhibits cytokine signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

The role of protein kinase C delta activation and STAT3 Ser727 phosphorylation in insulin-induced keratinocyte proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

The amino-terminal region of Tyk2 sustains the level of interferon alpha receptor 1, a component of the interferon alpha/beta receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Molecular mechanisms of cellular transformation by HTLV-1 Tax.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Mapping of a region within the N terminus of Jak1 involved in cytokine receptor interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Structural requirements of the interleukin-6 signal transducer gp130 for its interaction with Janus kinase 1: the receptor is crucial for kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Kinases as drug discovery targets in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Molecular cloning of a second subunit of the receptor for human granulocyte-macrophage colony-stimulating factor (GM-CSF): reconstitution of a high-affinity GM-CSF receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Identification of a nuclear Stat1 protein tyrosine phosphatase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Dimerization of the extracellular domain of granuloycte-colony stimulating factor receptor by ligand binding: a monovalent ligand induces 2:2 complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

The Jak/STAT pathway in model organisms: emerging roles in cell movement

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

The Stat family in cytokine signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Regulation of the immune system by SOCS family adaptor proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

CD45 regulated signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Repression of Stat3 activity by activation of mitogen-activated protein kinase (MAPK)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Protein kinase C delta associates with and phosphorylates Stat3 in an interleukin-6-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Partial impairment of cytokine responses in Tyk2-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

A gain-of-function mutation of JAK2 in myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Tyrosine 813 is a site of JAK2 autophosphorylation critical for activation of JAK2 by SH2-B beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Protein tyrosine phosphatase 1B antagonizes signalling by oncoprotein tyrosine kinase p210 bcr-abl in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

STAT3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

The JAK2 V617F mutation in de novo acute myelogenous leukemias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Normal and oncogenic forms of the receptor tyrosine kinase kit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Cytokine receptor signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Stats: transcriptional control and biological impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Determination of the transphosphorylation sites of Jak2 kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Stat5 activation is uniquely associated with cytokine signaling in peripheral T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Growth-hormone-receptor and cytokine-receptor-family signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and -gamma signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Targeted and extended acetylation of histones H4 and H3 at active and inactive genes in chicken embryo erythrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

JAK2 V617F in myeloid disorders: what do we know now, and where are we headed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Kinase activation through dimerization by human SH2-B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Jak3 and the pathogenesis of severe combined immunodeficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

A new modality for immunosuppression: targeting the JAK/STAT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

New strategies for immunosuppression: interfering with cytokines by targeting the Jak/Stat pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Jak2 is essential for signaling through a variety of cytokine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Developmental defects of lymphoid cells in Jak3 kinase-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

STATs as critical mediators of signal transduction and transcription: lessons learned from STAT5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Tumor suppressor genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

The structure, regulation and function of the Janus kinases (JAKs) and the signal transducers and activators of transcription (STATs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Inherited disorders of cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

The Jak1 SH2 domain does not fulfill a classical SH2 function in Jak/STAT signaling but plays a structural role for receptor interaction and up-regulation of receptor surface expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

JAKs, STATs and Src kinases in hematopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Receptor tyrosine kinases in normal and malignant haematopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Specific contribution of Tyk2 JH regions to the binding and the expression of the interferon alpha/beta receptor component IFNAR1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Janus kinases affect thrombopoietin receptor cell surface localization and stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Regulation of the Jak2 tyrosine kinase by its pseudokinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Expression of the suppressor of cytokine signaling-5 (SOCS5) negatively regulates IL-4-dependent STAT6 activation and Th2 differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

The T cell protein tyrosine phosphatase is a negative regulator of janus family kinases 1 and 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

The chemoattractants, IL-8 and formyl-methionyl-leucyl-phenylalanine, regulate granulocyte colony-stimulating factor signaling by inducing suppressor of cytokine signaling-1 expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

TYK2 is a key regulator of the surveillance of B lymphoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Essential role of Stat6 in IL-4 signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Homodimeric cross-over structure of the human granulocyte colony-stimulating factor (GCSF) receptor signaling complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

SLIM is a nuclear ubiquitin E3 ligase that negatively regulates STAT signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Clinical, genetic, and therapeutic insights into systemic mast cell disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Mutation screening for JAK2V617F: when to order the test and how to interpret the results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Polycythemia vera: scientific advances and current practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

DNA microarray analysis of stage progression mechanism in myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

SLIM trims STATs: ubiquitin E3 ligases provide insights for specificity in the regulation of cytokine signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

PIAS proteins promote SUMO-1 conjugation to STAT1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

SUMO-1 conjugation selectively modulates STAT1-mediated gene responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

JAK/STAT signal transduction: regulators and implication in hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Phosphorylation of the Stat1 transactivation domain is required for full-fledged IFN-gamma-dependent innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

A protein tyrosine kinase in the interferon alpha/beta signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Suppressor of cytokine signalling-1 gene silencing in acute myeloid leukaemia and human haematopoietic cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-gamma signal transduction pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

A hitchhiker's guide to the cullin ubiquitin ligases: SCF and its kin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Inhibitors of cytokine signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Stat4, a novel gamma interferon activation site-binding protein expressed in early myeloid differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

21 January 2018

The Janus kinases (Jaks)

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Stat5a/b are essential for normal lymphoid development and differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Negative regulation of cytokine signaling and immune responses by SOCS proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Stat3 dimerization regulated by reversible acetylation of a single lysine residue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

PTP1B regulates leptin signal transduction in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Roles of the SHP-1 tyrosine phosphatase in the negative regulation of cell signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

Identification of an acquired JAK2 mutation in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06206.X

10.1111/J.1365-2141.2006.06206.X

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference